Autolus Therapeutics (AUTL) Asset Writedowns and Impairment (2018 - 2026)

Autolus Therapeutics (AUTL) has 5 years of Asset Writedowns and Impairment data on file, last reported at $4.7 million in Q4 2025.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.5 million (up 2562.04% YoY) and the FY2025 annual result came in at $12.3 million, up 2871.01% from the prior year.
• Asset Writedowns and Impairment improved to $4.7 million in Q4 2025, from $4.3 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $4.7 million in Q4 2025 to a low of $18000.0 in Q4 2023.
• A 3-year average of $2.1 million and a median of $1.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 503.86% in 2025, down 503.86% in 2025.
• Tracing AUTL's Asset Writedowns and Impairment over 3 years: stood at $18000.0 in 2023, then jumped by 2200.0% to $414000.0 in 2024, then jumped by 1035.27% to $4.7 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $4.7 million (Q4 2025), $4.3 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.